◼ Archived
Business
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
Otsuka and Ionis report positive Phase 3 FUSION trial data for ulefnersen in treating a rare genetic form of ALS.
Otsuka
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.